Q32 Bio Inc
Q32 Bio Inc., located in Waltham, MA, is focused on the development of targeted immune therapeutics aimed at transforming the lives of patients with alopecia areata and other autoimmune and inflammatory diseases. The company is comprised of a skilled team of scientists, immunologists, and drug developers dedicated to rebalancing the immune system through innovative therapies.
The company's lead product candidate, Bempikibart, is a fully human monoclonal antibody designed to block interleukin-7 receptor alpha signaling, thereby re-regulating adaptive immune function. Currently, Bempikibart is undergoing evaluation in a Phase 2 clinical trial for patients with alopecia areata.
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2025. All rights reserved.